Bone-active drugs in premenopausal women with breast cancer under hormone-deprivation therapies.
Maria Francesca BirtoloRebecca PedersiniAndrea PalermoWalter VenaEmanuela MorenghiGiacomo CristofoliniBarbara PresciuttiniGaia TabaccoAnda Mihaela NaciuStella PigniMarta LaganàFederica MazzoleniDeborah CosentiniAntea CiafardiniMauro PaganiDavide FarinaLuca BalzariniAlberto ZambelliRosalba TorrisiLuisella CianferottiNicola NapoliAntonio Carlo BossiAndrea Gerardo LaniaAlfredo BerrutiGiovanna MantovaniPublished in: European journal of endocrinology (2024)
Premenopausal women under HDTs are at high risk of VFs in relationship with high BMI, densitometric diagnosis of osteoporosis, preexisting VFs, and family history of osteoporotic fractures. Vertebral fractures in this setting might be effectively prevented by bisphosphonates or denosumab.